Hims & Hers bounced back by 8.64 percent on Monday to close at $52.03 following announcements that it remains open to working ...

Connecticut passed a new law last week in an effort to lower its spending on weight-loss drugs for its state insurance ...

The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its ...

A pharmacist holds boxes of Ozempic, a semaglutide injection drug made by Novo Nordisk, in Provo, Utah, on March 29, 2023.

Proposals by Robert F. Kennedy Jr. and Bernie Sanders range from more disclosures in commercials to an outright ban.

Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

Adventurous speculators interested in a quick-strike opportunity may want to set their sights on Novo Nordisk (NYSE: NVO ).

Buying stocks that are trading at cheap valuations can set you up for some big gains later on. And it can minimize the risk ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...

The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

If you wish to turn $10,000 into $50,000 by 2035, you’re looking at a 400% gain over a 10-year horizon. In the past decade, ...

One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a ...